プレマーケット: 1.4277 0.0277 +1.98%

Cel-Sci Corp. (CVM)

Cel-Sci Corp. (CVM) 最新ニュース

Cel-Sci Corp. (CVM)

Cel-Sci Corp. (CVM) 最新ニュース

Cel-Sci: Fiscal Q2 Earnings Snapshot - Houston Chronicle

CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results - Investing News Network

Cel-Sci: Fiscal Q2 Earnings Snapshot | Nation/World | bdtonline.com - Bluefield Daily Telegraph

CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results - Business Wire

H.C. Wainwright analysts initates a Buy rating for Cel-Sci Corp. (CVM) – Knox Daily - Knox Daily

CEL-SCI Co. (NYSE:CVM) Director Acquires $27800.00 in Stock - Defense World

5 Worst-Performing Stocks Insiders are Buying in 2024 - Insider Monkey

Cel Sci director Watson buys $27799 in company shares - Investing.com

AACR Annual Meeting 2017 - CEL-SCI Corp - The Pharma Letter

Cel-Sci CEO Geert Kersten buys $41700 in company stock - Investing.com

Cel Sci exec Patricia Prichep buys $11120 in company stock - Investing.com

FDA greenlights CEL-SCI confirmatory study for Multikine - Investing.com

Why CEL-SCI (CVM) Shares Are Trading Higher - CEL-SCI (AMEX:CVM) - Benzinga

CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer - Yahoo Finance

Why CEL-SCI (CVM) Shares Are Trading Higher - CEL-SCI (AMEX:CVM) - Benzinga

Cel-Sci Corp Bolsters Board with Finance Expert Mario Gobbo - TipRanks.com - TipRanks

CEL-SCI Appoints Mario Gobbo to Its Board of Directors - Business Wire

CEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in ... - Yahoo Finance

CEL-SCI issues letter to shareholders regarding Multikine cancer therapy - TipRanks.com - TipRanks

CEL-SCI Corporation Issues Letter to Shareholders - Yahoo Finance

Cel-Sci Corp scientist presents new findings for rheumatoid arthritis treatment vaccine - Reuters

CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results - Yahoo Finance

Cel-Sci: Fiscal Q1 Earnings Snapshot - Quartz

CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock - Business Wire

CEL-SCI sets price for $7.75 million stock offering - Investing.com

CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head ... - Yahoo Finance

European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards ... - Yahoo Finance

CVM Stock Quote Price and Forecast - CNN

CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments - Yahoo Finance

Why U Power Shares Are Trading Lower By Around 54%? Here Are Other Stocks Moving In Monday's Mid-Day Session

UK'S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI's Multikine as Potential New Standard ... - Yahoo Finance

CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock - Business Wire

CEL-SCI Announces Pricing of $5 Million Offering of Common Stock - Yahoo Finance

CEL-SCI Issues Letter to Shareholders - Business Wire

CEL-SCI Readies Multikine Facility for Commercial Scale Production - Contract Pharma

5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI's Target Population, Cutting Risk of ... - Business Wire

CEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results - Yahoo Finance

CEL-SCI Concludes Positive Meeting With U.S. FDA Concerning Multikine's Approval for Head & Neck Cancer - Business Wire

Anna Lloyd Obituary - Bel Air, MD - Dignity Memorial

CEL-SCI to Pursue Canada's Conditional Approval Pathway for Multikine in the Treatment of Head & Neck Cancer - Business Wire

CEL-SCI's Multikine Phase 3 Cancer Study Shows 43% Survival Extension - Business Wire

The 12 Best Medical Stocks Under 10 Dollars To Buy Now - The Stock Dork

CEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results Posted on Clinicaltrials.gov - Business Wire

CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors - Business Wire

CEL-SCI Corporation Completes Commercial-Scale Buildout of Multikine Manufacturing Facility - Business Wire

The List of Big 'Short Squeeze' Opportunities - LiveTradingNews

Covid-19 immunotherapy to be developed by CEL-SCI. - Pharmaceutical Technology

Vienna biotech Cel-Sci faces delisting threat on heels of lawsuit win - Washington Business Journal - The Business Journals

'The drug was not the problem:' Vienna biotech Cel-Sci wins lawsuit after delayed trial - Washington Business Journal - The Business Journals

Cel-Sci Wins Breach of Contract Ruling against Clinical Research Organization inVentiv, Now Known as Syneos Health - Business Wire

CVMに似た銘柄